Paul Damon & Associates, Inc. Eli Lilly & CO Transaction History
Paul Damon & Associates, Inc.
- $191 Billion
- Q2 2025
A detailed history of Paul Damon & Associates, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Paul Damon & Associates, Inc. holds 467 shares of LLY stock, worth $299,281. This represents 0.19% of its overall portfolio holdings.
Number of Shares
467
Previous 255
83.14%
Holding current value
$299,281
Previous $211 Million
72.85%
% of portfolio
0.19%
Previous 0.13%
Shares
2 transactions
Others Institutions Holding LLY
# of Institutions
4,399Shares Held
807MCall Options Held
9.9MPut Options Held
10.9M-
Lilly Endowment Inc Indianapolis, IN96MShares$61.5 Billion0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA79.2MShares$50.8 Billion1.22% of portfolio
-
Black Rock Inc. New York, NY65.9MShares$42.2 Billion1.37% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA51.3MShares$32.9 Billion26.07% of portfolio
-
State Street Corp Boston, MA34.4MShares$22.1 Billion1.2% of portfolio
About ELI LILLY & Co
- Ticker LLY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 950,174,976
- Market Cap $609B
- Description
- Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...